SA515370275B1 - تحضير روسيورونيوم يؤدي إلى تقليل الألم، طريقة لإنتاجه، وطريقة لخفض/ ألم الأوعية الدموية ليكون محفز باستخدامه - Google Patents
تحضير روسيورونيوم يؤدي إلى تقليل الألم، طريقة لإنتاجه، وطريقة لخفض/ ألم الأوعية الدموية ليكون محفز باستخدامهInfo
- Publication number
- SA515370275B1 SA515370275B1 SA515370275A SA515370275A SA515370275B1 SA 515370275 B1 SA515370275 B1 SA 515370275B1 SA 515370275 A SA515370275 A SA 515370275A SA 515370275 A SA515370275 A SA 515370275A SA 515370275 B1 SA515370275 B1 SA 515370275B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- buffer solution
- same
- pain
- induced
- producing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
تحضير روسيورونيوم يؤدي إلى تقليل الألم، طريقة لإنتاجه، وطريقة لخفض/ ألم الأوعية الدموية ليكون محفز باستخدامه ROCURONIUM PREPARATION CAUSING LESS PAIN, METHOD FOR PRODUCING THE SAME, AND METHOD FOR REDUCING AND/OR ALLEVIATING VASCULAR PAIN TO BE INDUCED USING THE SAME الملخـــص تم تقديم تحضير روسيورونيوم rocuronium مصمم للحد من ألم الأوعية الدموية vascular pain ليكون محفز. تحضير الروسيورونيوم يحتوي على روسيورونيوم ومحلول عازل buffer solution، وله نسبة حموضة titratable acidity من 100 مل مكافئ أو أقل. قد يكون المحلول العازل محلول أسيتات عازل acetate buffer solution، محلول سيترات عازل citrate buffer solution، محلول فورمات عازل formate buffer solution، محلول طرطرات عازل tartrate buffer solution، محلول فوسفات عازل phosphate buffer solution، محلول عازل من حمض جلايسين الهيدروكلوريك glycine-hydrochloric acid buffer solution، أو محلول عازل من حمض فوسفات سيتريك citric acid-phosphate buffer solution. شكل 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013138218 | 2013-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA515370275B1 true SA515370275B1 (ar) | 2021-06-10 |
Family
ID=52143574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA515370275A SA515370275B1 (ar) | 2013-07-01 | 2015-12-14 | تحضير روسيورونيوم يؤدي إلى تقليل الألم، طريقة لإنتاجه، وطريقة لخفض/ ألم الأوعية الدموية ليكون محفز باستخدامه |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10821119B2 (ar) |
| EP (1) | EP3017817B1 (ar) |
| JP (1) | JP5781698B2 (ar) |
| KR (2) | KR101803857B1 (ar) |
| CN (2) | CN110251459A (ar) |
| AU (1) | AU2014285324B2 (ar) |
| BR (1) | BR112015030877B1 (ar) |
| CA (1) | CA2914154C (ar) |
| DK (1) | DK3017817T3 (ar) |
| ES (1) | ES2794529T3 (ar) |
| HK (1) | HK1224183A1 (ar) |
| IL (1) | IL243363B (ar) |
| MX (1) | MX366310B (ar) |
| NZ (1) | NZ714485A (ar) |
| PH (1) | PH12015502850B1 (ar) |
| PT (1) | PT3017817T (ar) |
| RU (1) | RU2680405C2 (ar) |
| SA (1) | SA515370275B1 (ar) |
| SG (1) | SG11201510733YA (ar) |
| WO (1) | WO2015001995A1 (ar) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015198456A1 (ja) * | 2014-06-26 | 2015-12-30 | 丸石製薬株式会社 | 安定性を改善したロクロニウム製剤 |
| CN111374942B (zh) * | 2018-12-30 | 2022-09-13 | 鲁南制药集团股份有限公司 | 一种甾体类肌松药注射液及其制备方法 |
| US20230014293A1 (en) | 2021-07-02 | 2023-01-19 | Fresenius Kabi Austria Gmbh | Aqueous, room-temperature stable rocuronium composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8708886D0 (en) | 1987-04-14 | 1987-05-20 | Akzo Nv | 2beta-morpholino-androstane derivatives |
| US5418226A (en) * | 1992-04-22 | 1995-05-23 | Akzo N.V. | Monoquaternary 2,16-bispiperidinylandrostane derivatives |
| JP2925054B2 (ja) | 1993-08-20 | 1999-07-26 | 宇部興産株式会社 | 疎水性物質の親水性化方法 |
| US6030941A (en) * | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
| AU1874499A (en) | 1997-11-27 | 1999-06-16 | Akzo Nobel N.V. | A pharmaceutical formulation of monoquaternary 2,16-bispiperidinylandrostane forintramuscular administration |
| US6911455B2 (en) * | 1999-12-22 | 2005-06-28 | Smithkline Beecham Corporation | Methods for preparing pharmaceutical formulations |
| AU2006315610A1 (en) | 2005-11-14 | 2007-05-24 | Peter D. Winch | Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts |
| CN101400369A (zh) * | 2005-11-14 | 2009-04-01 | P·D·温施 | 注射药物及其药学上可接受的盐的新颖的有色溶液 |
| EP1967188B1 (en) * | 2005-12-29 | 2012-01-25 | Nipro Corporation | Pharmaceutical preparation of an aqueous solution containing platinum complex |
| RU2329799C1 (ru) * | 2006-11-13 | 2008-07-27 | Федеральное государственное учреждение Третий Центральный Военный Клинический госпиталь имени А.А. Вишневского Министерства обороны РФ | Способ анестезии при проведении адреналэктомии по поводу феохромоцитомы надпочечника |
| WO2008065142A1 (en) * | 2006-11-29 | 2008-06-05 | N.V. Organon | Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative |
| EP2647370B1 (en) | 2010-11-29 | 2019-02-27 | Otsuka Pharmaceutical Factory, Inc. | Infusion preparation |
-
2014
- 2014-06-23 DK DK14820424.1T patent/DK3017817T3/da active
- 2014-06-23 MX MX2015017549A patent/MX366310B/es active IP Right Grant
- 2014-06-23 SG SG11201510733YA patent/SG11201510733YA/en unknown
- 2014-06-23 NZ NZ714485A patent/NZ714485A/en unknown
- 2014-06-23 PT PT148204241T patent/PT3017817T/pt unknown
- 2014-06-23 KR KR1020167002704A patent/KR101803857B1/ko active IP Right Grant
- 2014-06-23 AU AU2014285324A patent/AU2014285324B2/en active Active
- 2014-06-23 BR BR112015030877-5A patent/BR112015030877B1/pt active IP Right Grant
- 2014-06-23 ES ES14820424T patent/ES2794529T3/es active Active
- 2014-06-23 RU RU2016102844A patent/RU2680405C2/ru active
- 2014-06-23 KR KR1020177015581A patent/KR102060160B1/ko active IP Right Grant
- 2014-06-23 US US14/898,259 patent/US10821119B2/en active Active
- 2014-06-23 EP EP14820424.1A patent/EP3017817B1/en active Active
- 2014-06-23 WO PCT/JP2014/066504 patent/WO2015001995A1/ja active Application Filing
- 2014-06-23 CN CN201910588071.0A patent/CN110251459A/zh active Pending
- 2014-06-23 JP JP2014530435A patent/JP5781698B2/ja active Active
- 2014-06-23 CA CA2914154A patent/CA2914154C/en active Active
- 2014-06-23 CN CN201480037714.8A patent/CN105431151A/zh active Pending
-
2015
- 2015-12-14 SA SA515370275A patent/SA515370275B1/ar unknown
- 2015-12-22 PH PH12015502850A patent/PH12015502850B1/en unknown
- 2015-12-27 IL IL243363A patent/IL243363B/en active IP Right Grant
-
2016
- 2016-10-27 HK HK16112421.6A patent/HK1224183A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201614068A (en) | Fucosidase from bacteroides and methods using the same | |
| HK1218932A1 (zh) | 酸度上升被抑制了的發酵乳及其製造方法 | |
| MX2015009037A (es) | Enjuague nasal con miel. | |
| FR2969495B1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
| MX2015007147A (es) | Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab. | |
| PH12016500667A1 (en) | Array of age-tailored infant formula with optimum protein content and lactose content | |
| MY175057A (en) | Method for preparing natural neutral flavor | |
| AU2018201444B2 (en) | High fat human milk products | |
| SA515370275B1 (ar) | تحضير روسيورونيوم يؤدي إلى تقليل الألم، طريقة لإنتاجه، وطريقة لخفض/ ألم الأوعية الدموية ليكون محفز باستخدامه | |
| WO2014152754A3 (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens | |
| PH12016500608A1 (en) | Cyclic thienouracil-carboxamides and use thereof | |
| WO2014145236A3 (en) | The use of sdf-1 to mitigate scar formation | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| GB2490854A (en) | Method of treatment or prevention of hair loss or for the enhancement of hair growth | |
| BR112014029308A2 (pt) | um método de melhorar a função hepática | |
| IN2013MU01286A (ar) | ||
| MX2016005645A (es) | Composicion farmaceutica topica de acitretina. | |
| MX2016007635A (es) | Serie de formulas infantiles adaptadas a la edad con contenido de lactosa y contenido de proteinas optimos. | |
| TH1501007930A (th) | สารเตรียมโรคิวโรเนียมที่ช่วยให้ความเจ็บปวดลดลง, วิธีการสำหรับการผลิตสิ่งที่ คล้ายกัน, และวิธีการสำหรับการลด และ/หรือการบรรเทาความเจ็บปวดของหลอด เลือดที่ถูกชักนำโดยการใช้สิ่งที่คล้ายกัน | |
| UA47183U (ru) | Способ диагностики синдрома сосудистых умеренных когнитивных нарушений | |
| LV14644A (lv) | Krēms psoriāzes izraisītu patoloģisku ādas izmaiņu ārstēšanai | |
| UA53044U (ru) | Способ лечения кефалогематомы у новорожденных детей | |
| PH22012000728Y1 (en) | Method of preserving coconut water and fruit extracts | |
| MX2013006633A (es) | Beta-hidroxi-gamma-aminofosfonatos para el tratamiento de trastornos inmunes. | |
| NZ629711A (en) | Anti-inflammatory compositions, methods and uses thereof |